Ayman Bishay, MD
Pulmonary Disease · Hanover, PANPI 1093916355
Payments from drug & device makers
Across 26 payments — averaging $235.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Sanofi-aventis U.S. LLC$100
- AstraZeneca$64
- Sanofi$37
- Ambu Inc.$37
- Harmony Biosciences LLC$24
- plus $41 from 3 others
What the payments were for
- Travel & lodging$1,18519%
- Food & beverage$59710%
- Education$4,33471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 14 | $5,813 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| AstraZeneca | 3 | $64 |
| Sanofi | 1 | $37 |
| Ambu Inc. | 3 | $37 |
| Harmony Biosciences LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Veran Medical Technologies, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,665
How this compares
$6,117 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $167,034 |
| Dupixent PenDupilumab | 26 | $96,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $91,562 |
| Arnuity ElliptaFluticasone Furoate | 28 | $13,959 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,377 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,687 |
| Roflumilast | 33 | $5,124 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $4,184 |
| Ventolin HfaAlbuterol Sulfate | 15 | $1,960 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $1,594 |
| Fluticasone Propionate | 17 | $947 |
| Montelukast Sodium | 103 | $714 |
| Ipratropium Bromide | 16 | $506 |
| Ropinirole Hcl | 79 | $413 |
| Gabapentin | 39 | $263 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Hanover
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.